The notice of allowance is the USPTO’s official communication that the company’s application has successfully completed examination and that a patent will be issued.
Once issued, the patent will provide broad coverage for company’s abuse-deterrent, sustained-release, orally administered formulation platform, known as DETERx. Company’s lead DETERx product candidate, COL-003, a formulation of sustained release oxycodone, will be covered by the patent.